The stock of Cellectar Biosciences Inc (CLRB) has seen a -15.72% decrease in the past week, with a 7.58% gain in the past month, and a 5.00% flourish in the past quarter. The volatility ratio for the week is 8.93%, and the volatility levels for the past 30 days are at 9.70% for CLRB. The simple moving average for the past 20 days is -9.58% for CLRB’s stock, with a -78.54% simple moving average for the past 200 days.
Is It Worth Investing in Cellectar Biosciences Inc (NASDAQ: CLRB) Right Now?
CLRB has 36-month beta value of 0.46. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CLRB is 45.31M, and currently, short sellers hold a 6.45% ratio of that float. The average trading volume of CLRB on April 02, 2025 was 1.69M shares.
CLRB) stock’s latest price update
Cellectar Biosciences Inc (NASDAQ: CLRB) has seen a rise in its stock price by 5.00 in relation to its previous close of 0.29. However, the company has experienced a -15.72% decline in its stock price over the last five trading sessions. zacks.com reported 2025-03-18 that Here is how Cellectar Biosciences, Inc. (CLRB) and Cencora (COR) have performed compared to their sector so far this year.
Analysts’ Opinion of CLRB
Many brokerage firms have already submitted their reports for CLRB stocks, with Ladenburg Thalmann repeating the rating for CLRB by listing it as a “Buy.” The predicted price for CLRB in the upcoming period, according to Ladenburg Thalmann is $13 based on the research report published on December 05, 2024 of the previous year 2024.
ROTH Capital gave a rating of “Buy” to CLRB, setting the target price at $10 in the report published on January 21st of the previous year.
CLRB Trading at 0.75% from the 50-Day Moving Average
After a stumble in the market that brought CLRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.61% of loss for the given period.
Volatility was left at 9.70%, however, over the last 30 days, the volatility rate increased by 8.93%, as shares surge +1.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.62% upper at present.
During the last 5 trading sessions, CLRB fell by -15.56%, which changed the moving average for the period of 200-days by -90.86% in comparison to the 20-day moving average, which settled at $0.3391. In addition, Cellectar Biosciences Inc saw 2.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLRB starting from Longcor Jarrod, who purchase 30,000 shares at the price of $0.28 back on Jan 10 ’25. After this action, Longcor Jarrod now owns 83,141 shares of Cellectar Biosciences Inc, valued at $8,400 using the latest closing price.
Stock Fundamentals for CLRB
The total capital return value is set at -3.22. Equity return is now at value -4693.38, with -237.45 for asset returns.
Based on Cellectar Biosciences Inc (CLRB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -96.32.
Currently, EBITDA for the company is -51.78 million with net debt to EBITDA at 0.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.58.
Conclusion
To put it simply, Cellectar Biosciences Inc (CLRB) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
